{"id":"fviii-products","brandName":"FVIII products","genericName":"FVIII products","companyId":"bayer","companyName":"Bayer","phase":"phase_2","status":"active","modality":"Small molecule","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Bayer's FVIII products are advancing through various clinical trials, including gene therapy and novel replacement therapies for severe hemophilia A. These efforts aim to improve safety, efficacy, and patient outcomes, positioning Bayer as a leader in hemophilia treatment.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"FVIII products work by providing the necessary clotting factor VIII to help the blood to form a clot. This is particularly important for individuals with hemophilia A, a genetic disorder characterized by the deficiency of this clotting factor. By replacing or supplementing the missing or defective FVIII, these products help to prevent or control bleeding episodes.","oneSentence":"FVIII products replace or supplement the missing or defective clotting factor VIII in the blood to help the blood to clot normally.","_ai_confidence":"high"},"administration":{},"safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Pain"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Injection site reaction"}]},"trials":[],"indications":{"approved":[{"name":"Hemophilia A"},{"name":"Hemophilia A with inhibitors"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}